Community-acquired pneumonia: risk and prognosis
Abstract
<b>Purpose:</b> to assess factors and risks of development of community-acquired pneumonia. <b>Materials and methods.</b> The subject and object of this research was copy of data from the medical history of 7709 patients, treated in the pulmonology department of RSSPMCPhP in the period 2015-2018. <b>Results:</b> According to a retrospective study, the proportion of community-acquired pneumonia (CAP) was 6.44%. Chronic bronchopulmonary diseases and the cardiovascular system diseases were revealed in 54.7% and 41.8% in CAP patients. The proportion of CAP without comorbidity was 29.7%. 65.4% of patients without comorbid condition were 40 years or younger; 96.3% of patients with CBPD and up to 93.6% of patients with CVD were older than 40 years. The incidence of CAP with CVD was 2 times more frequent among women (64.5%). 66.8% of treated persons with CAP had the fact of late hospitalization, which lasted more than 7 days. 58.1% of lately hospitalized patients had CBPD, and 23.7% of patients had CVD as comorbidities. 20.4% of patients were hospitalized for more than 10 days. In patients with a duration of treatment of more than 10 days, up to 56.8% of patients had concomitant CKD, 31.8% had CVD, and only 17% of patients with CAP had no diagnosed comorbid condition. <b>Conclusion:</b> Community-acquired pneumonia developed on the background of chronic pathology of respiratory system is considered as a cost-demanding clinical case, having both the course and treatment features, and the development of measures for mandatory pneumococcal vaccination of people with chronic bronchopulmonary pathology.